AzTrials
AzTrials

Gastric CancerTAP-WELPASSNCT07452471

Comparison of the Postoperative Analgesic Effects of the Temperature-responsive Gel Mixed With Local Anesthetics Application and Ultrasound-guided Transversus Abdominis Plane Block in Patients Undergoing Laparoscopic Gastrectomy

A study testing Ultrasound-guided Transversus Abdominis Plane (TAP) Block and Ropivacaine-Poloxamer 407 Hydrogel (Welpass®) in people with Gastric Cancer and Postoperative Pain, run by Gyeong-Jo Byeon, MD, PhD at 1 site in South Korea.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

This study is a single-center, prospective, randomized controlled trial designed to compare two established postoperative analgesic strategies in adult patients undergoing laparoscopic gastrectomy under general anesthesia. Read more about this study

Who is it for?
Ages 19 years and older
Conditions the study is for
Gastric Cancer, Postoperative Pain
What is being tested?
Ultrasound-guided Transversus Abdominis Plane (TAP) Block and Ropivacaine-Poloxamer 407 Hydrogel (Welpass®)
Could I receive a placebo?
No, everyone receives an active treatment
How many people
80 participants
Where
1 siteSouth Korea
Study dates
12 Feb 2026to 11 Feb 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 19 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adults aged 19 years or older undergoing laparoscopic gastrectomy under general anesthesia
  • American Society of Anesthesiologists (ASA) physical status I-III

Who cannot join

  • Known hypersensitivity or allergy to local anesthetics
  • Presence of autoimmune disease or dermatologic conditions such as keloids
  • Conversion from laparoscopic surgery to open surgery
  • Pregnant women
  • Chronic opioid use for persistent pain
  • Inability to communicate effectively, making pain assessment difficult
  • Refusal to participate in the study

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Gyeong Jo Byun, MD contact

82-10-5663-1713

byeongj@pusan.ac.kr

South Korea1 site
  • Yangsan Pusan National University Hospital

    Yangsan, Gyeongsamnamdo, 50612

    Gyeongjo Byun, MD, 82-10-5663-1713, byeongj@pusan.ac.kr

Other trials in South Korea

About this study

This study is a single-center, prospective, randomized controlled trial designed to compare two established postoperative analgesic strategies in adult patients undergoing laparoscopic gastrectomy under general anesthesia.

Effective pain control after laparoscopic gastrectomy is essential to promote early recovery, facilitate ambulation, reduce opioid consumption, and improve overall postoperative outcomes. Although minimally invasive techniques reduce surgical trauma, patients frequently experience moderate postoperative pain arising from abdominal wall incisions and trocar insertion sites.

Read more

This trial compares two analgesic approaches:

Ultrasound-guided bilateral transversus abdominis plane (TAP) block using 0.2% ropivacaine

Local application of a thermosensitive ropivacaine-poloxamer 407 hydrogel formulation (Welpass®) applied to the surgical site at the end of surgery

A total of 80 patients (age ≥19 years, American Society of Anesthesiologists physical status I-III) scheduled for elective laparoscopic gastrectomy will be enrolled at a single institution. Participants will be randomly assigned in a 1:1 ratio to either the TAP block group (n=40) or the hydrogel group (n=40).

In the TAP block group, 0.2% ropivacaine will be injected bilaterally between the internal oblique and transversus abdominis muscles under ultrasound guidance at the completion of surgery.

In the hydrogel group, a mixture of ropivacaine and poloxamer 407-based gel (Welpass®) will be prepared and applied locally to the surgical site, including the fascial plane and subcutaneous tissue, prior to wound closure.

All patients will receive standardized general anesthesia and postoperative patient-controlled analgesia (PCA) according to institutional protocols.

The primary objective of the study is to compare postoperative pain intensity between the two groups. Pain will be assessed using the Visual Analog Scale (VAS) immediately upon arrival in the post-anesthesia care unit (PACU), just before PACU discharge, and at 12 and 24 hours after surgery.

Secondary outcomes include:

  • Total PCA consumption within 48 hours
  • Additional analgesic use (total dose and frequency)
  • Time to first flatus
  • Time to ambulation
  • Length of hospital stay
  • Incidence of postoperative nausea and vomiting (PONV)

Safety will be evaluated by monitoring adverse events, including signs of local anesthetic systemic toxicity or other serious complications. Both analgesic techniques involve medications and procedures that are widely used in routine clinical practice. The study uses approved drugs within standard dosing ranges and is conducted by experienced clinicians. If a serious adverse event suspected to be related to the intervention occurs, appropriate medical management will be provided immediately, and the Institutional Review Board (IRB) will be notified in accordance with regulatory requirements.

Participants may be withdrawn from the study if they experience a serious adverse reaction related to the intervention, if conversion to open surgery occurs, or if they choose to withdraw consent.

The aim of this study is to determine whether local application of sustained-release ropivacaine hydrogel provides analgesic efficacy comparable or superior to ultrasound-guided TAP block. The findings may help identify an effective and safe postoperative pain management strategy for patients undergoing laparoscopic gastrectomy and contribute to optimizing multimodal analgesia protocols in minimally invasive gastric surgery.

Being tested
Ultrasound-guided Transversus Abdominis Plane (TAP) Block, Ropivacaine-Poloxamer 407 Hydrogel (Welpass®)
Medical subject headings
Stomach Neoplasms, Pain, Postoperative

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Ultrasound-guided Transversus Abdominis Plane (TAP) BlockProcedure or surgery

    Bilateral ultrasound-guided injection of 0.2% ropivacaine between the internal oblique and transversus abdominis muscles at the end of surgery

  • Ropivacaine-Poloxamer 407 Hydrogel (Welpass®)Drug

    Local application of a thermosensitive hydrogel containing ropivacaine and poloxamer 407 to the fascial and subcutaneous layers at the surgical site prior to wound closure

Study groups in NCT07452471
Study groupRoleWhat they receive
TAP Block GroupActive comparatorParticipants receive bilateral ultrasound-guided transversus abdominis plane (TAP) block with 0.2% ropivacaine at the completion of laparoscopic gastrectomy. Standardized general anesthesia and postoperative patient-controlled analgesia (PCA) are provided
Receives: Procedure: Ultrasound-guided Transversus Abdominis Plane (TAP) Block
Ropivacaine-Poloxamer Hydrogel GroupExperimentalParticipants receive local application of ropivacaine-poloxamer 407 thermosensitive hydrogel (Welpass®) at the surgical site following laparoscopic gastrectomy. Standardized general anesthesia and postoperative PCA are provided
Receives: Drug: Ropivacaine-Poloxamer 407 Hydrogel (Welpass®)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Postoperative Pain Intensity

    Postoperative pain intensity measured using the Visual Analog Scale (VAS, 0-10) immediately upon arrival in the post-anesthesia care unit (PACU) and just before PACU discharge. The VAS ranges from 0 (no pain) to 10 (worst imaginable pain). Mean pain scores will be compared between the two groups

    Measured: postoperative period(immediately upon arrival in PACU, at PACU discharge, 12,24 hours after surgery)

Secondary outcomes (7)
  1. Total Patient-Controlled Analgesia (PCA) Consumption

    Total cumulative dose of intravenous patient-controlled analgesia administered during the first 48 hours after surgery.

    Measured: 48 hours postoperatively

  2. Total Rescue Analgesic Dose

    Total cumulative dose of additional rescue analgesics administered within 48 hours after surgery.

    Measured: 48 hours postoperatively

  3. Number of Rescue Analgesic Administrations

    Total number of additional rescue analgesic administrations within 48 hours after surgery.

    Measured: 48 hours postoperatively

  4. Number of PONV Episodes

    Total number of postoperative nausea and vomiting episodes occurring within 48 hours after surgery.

    Measured: 48 hours postoperatively

  5. Time to First Flatus

    Time from the end of surgery to the first passage of flatus, measured in hours.

    Measured: From the end of surgery until the first documented passage of flatus, assessed up to 7 days postoperatively

  6. Time to First Ambulation

    Time from the end of surgery to first ambulation, measured in hours.

    Measured: From end of surgery to first ambulation, assessed up to 7 postoperative days

  7. Length of Postoperative Hospital Stay

    Duration of hospitalization from the date of surgery to the date of discharge, measured in days.

    Measured: From date of surgery to date of discharge, assessed up to 30 days postoperatively

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Mar 2026
  2. Study start12 Feb 2026 (estimated)
  3. Primary completion11 Feb 2027 (estimated)
  4. Study completion11 Feb 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Investigator, Outcomes assessor
Enrolment
80 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07452471
Sponsor's protocol ID
WELPASS-TAP
Other IDs
IRB 21-2026-002
Acronym
TAP-WELPASS
Status last verified
Feb 2026
First submitted
20 Feb 2026
Last updated
5 Mar 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: Individual participant data will not be shared due to institutional policies and restrictions outlined in the informed consent process. The study is a single-center clinical trial, and no plans for public data repository submission have been established

Questions about this trial

What is this clinical trial studying?

A study testing Ultrasound-guided Transversus Abdominis Plane (TAP) Block and Ropivacaine-Poloxamer 407 Hydrogel (Welpass®) in people with Gastric Cancer and Postoperative Pain, run by Gyeong-Jo Byeon, MD, PhD at 1 site in South Korea.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 5 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Gyeong Jo Byun, MD (82-10-5663-1713, byeongj@pusan.ac.kr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Postoperative Pain Intensity (time frame: postoperative period(immediately upon arrival in PACU, at PACU discharge, 12,24 hours after surgery)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Mar 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in